Late-stage biotech CytoDyn Inc (CYDY) has announced that it has provided its Top-line Report from its recently completed Phase 2 trial of leronlimab for COVID-19 patients with mild-to-moderate symptoms to the U.S. Food and Drug Administration (FDA), and requested emergency use approval. https://finance.yahoo.com/news/cytodyn-requests-covid-19-emergency-125739300.html
NOWHERE does is say Emergency Use Authorization (EUA) was applied for.